ALLMedicine™ Eosinophilic Granulomatosis With Polyangiitis Center
Research & Reviews 355 results
https://doi.org/10.1111/ijd.16214
International Journal of Dermatology; Shakshouk H, Gibson LE
May 17th, 2022 - ANCA-associated vasculitis (AAV) may present a wide array of dermatological manifestations. Patients may remain ANCA negative, rendering diagnosis challenging for dermatologists if they depend heavily on ANCA testing to either confirm or rule out ...
https://clinicaltrials.gov/ct2/show/NCT00315380
May 17th, 2022 - EGPA, also known as allergic granulomatosis angiitis, is a systemic vasculitis. EGPA is marked by three distinct symptoms: asthma; eosinophilia, evidenced by an excessive number of eosinophils in the blood and tissues; and vasculitis involving the...
https://doi.org/10.1016/j.amjoto.2022.103485
American Journal of Otolaryngology; Stavrakas M, Smith R et. al.
May 15th, 2022 - ANCA-associated vasculitides (AAV) represent a group of diagnoses, including granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and microscopic polyangiitis (MPA). Most commonly, they present initially wit...
https://doi.org/10.55563/clinexprheumatol/ahyqld
Clinical and Experimental Rheumatology; Belfeki N, Abroug S et. al.
May 7th, 2022 - Eosinophilic granulomatosis with polyangiitis (EGPA) is characterised by many features, including asthma, allergic rhinitis, peripheral and tissue eosinophilia, and vasculitis. Its pathophysiology is still unclear and we suggest that there are dif...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058677
BMJ Case Reports; Gill R, Rizvi M et. al.
Apr 30th, 2022 - A middle age man with a history of diabetes mellitus type 2, hypertension, migraine and eosinophilic granulomatosis with polyangiitis (EGPA) with polyneuropathy in remission presented with paresthesia and motor weakness soon after receiving the Pf...
Guidelines 2 results
https://doi.org/10.1002/art.41982
Arthritis & Rheumatology (Hoboken, N.J.); Grayson PC, Ponte C et. al.
Feb 3rd, 2022 - To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) iden...
https://doi.org/10.1002/art.41773
Arthritis & Rheumatology (Hoboken, N.J.); Chung SA, Langford CA et. al.
Jul 9th, 2021 - To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic...
Drugs 1 results see all →
Clinicaltrials.gov 9 results
https://clinicaltrials.gov/ct2/show/NCT00315380
May 17th, 2022 - EGPA, also known as allergic granulomatosis angiitis, is a systemic vasculitis. EGPA is marked by three distinct symptoms: asthma; eosinophilia, evidenced by an excessive number of eosinophils in the blood and tissues; and vasculitis involving the...
https://clinicaltrials.gov/ct2/show/NCT04316494
Mar 18th, 2022 - This is a multi-centre, randomised, placebo-controlled, double-blind study to evaluate if hydroxychloroquine in combination with background maintenance therapy improves the clinical response and quality of life in patients with AAV. 76 participant...
https://clinicaltrials.gov/ct2/show/NCT04720196
Mar 8th, 2022 - Vasculitic neuropathies (VN) are a group of disorders resulting from inflammation of predominantly small vessels with destruction of their walls and subsequent ischemic damage of peripheral nerves. Neural damage may or may not coexist with the dam...
https://clinicaltrials.gov/ct2/show/NCT02807103
Apr 14th, 2021 - Systemic vasculitides are inflammatory diseases of blood vessels, among which anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are often severe with life-threatening manifestations or complications. AAV include granulomato...
https://clinicaltrials.gov/ct2/show/NCT03455686
Sep 3rd, 2020 - The primary objective of this study is to evaluate the ventilation defect percent (VDP), apparent diffusion coefficient (ADC) and/or the signal-to-noise ratio (SNR) obtained by analysis of hyperpolarized 129Xe MRI at one or more time-points (over ...
News 22 results
https://www.medscape.com/viewarticle/963134
Nov 17th, 2021 - Rituximab didn't perform any worse or better at inducing remission after a year in patients with eosinophilic granulomatosis with polyangiitis (EGPA) than did conventional treatment with cyclophosphamide in the phase 3 REOVAS trial conducted in Fr...
https://www.medscape.com/viewarticle/954873
Jul 15th, 2021 - Three new guidelines from the American College of Rheumatology, in partnership with the Vasculitis Foundation, offer evidence-based recommendations for managing and treating six different forms of systemic vasculitis. Dr Sharon Chung "It's not unu...
https://www.staging.medscape.com/viewarticle/938221
Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...
https://www.medpagetoday.com/rheumatology/generalrheumatology/86348
May 7th, 2020 - Mycophenolate mofetil (CellCept) was as effective as cyclophosphamide for remission induction in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Japanese researchers reported. In a meta-analysis of four clinical trials, the overa...
https://www.medscape.com/viewarticle/918328
Sep 12th, 2019 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to children as young as 6 years old with severe eosinophilic asthma. Mepolizumab subcutaneous injection was first approved in the Unite...
